County-Level Context and Differential Policy Impacts on Buprenorphine Use Among Medicaid Enrollees with Opioid Use Disorder in Kentucky, 2018–2025
- 1Department of Biostatistics, University of Kentucky, 111 Washington Ave, Lexington, KY 40536
- 2Department of Pharmacy Practice and Science, University of Kentucky College of Pharmacy, 789 S. Limestone, Lexington, KY 40536
Abstract
PURPOSE: To estimate changes in buprenorphine use among Kentucky Medicaid enrollees with opioid use disorder (OUD) after policy changes and pandemic disruptions, and whether impacts differed by county-level context, primarily rurality and, secondarily, opioid treatment program (OTP) availability. METHODS: We analyzed Kentucky Medicaid claims from January 2018 through June 2025, identifying enrollees with diagnosed OUD to construct 10,800 county-month observations. Logistic regression fitted with weighted generalized estimating equations was used for statistical modeling of an interrupted time series (ITS) design to assess changes in the monthly proportion of enrollees with OUD receiving buprenorphine. Interruptions included removal of prior authorization (PA) requirements for transmucosal buprenorphine, methadone coverage initiation, COVID-19-related policy changes, and federal X-waiver elimination. Rurality and OTP availability were evaluated as effect modifiers. RESULTS: The proportion of enrollees with OUD receiving buprenorphine increased from 0.29 to 0.45 across the study period. PA removal was associated with an immediate increase in the odds of buprenorphine use (odds ratio [OR]=1.043; 95% confidence interval [CI]=1.025, 1.061), corresponding to a 1.4-percentage-point increase. X-waiver elimination was associated with a sustained increase in trend (OR 1.007; 95% CI 1.004-1.010). Differential effects by rurality were limited to the COVID-19 period. Counties without an OTP responded more strongly to PA removal than counties with an OTP (P = 0.037). CONCLUSIONS: Removal of administrative and regulatory barriers was associated with increased buprenorphine use among Kentucky Medicaid enrollees with OUD, with effects varying by county-level context, particularly OTP availability.
Related
- Comparative risk of injury among users of benzodiazepines and related drugs concomitantly with clarithromycin versus azithromycin: a retrospective cohort study of US Medicaid enrollees.
- Comparative health outcomes of buprenorphine versus methadone treatment for opioid use disorder: a retrospective propensity score-matched cohort study in the global federated electronic health record network
- Analysis of the costs and reach of transportation services to reduce barriers to opioid use disorder (OUD) treatment: evidence from the Kentucky HEALing Communities Study
- An Ultra-Long-Acting Buprenorphine Prodrug Ion-Pair for Opioid Use Disorder
- Postpartum contraception receipt among Oregon Medicaid-funded births with stimulant and substance use disorder.
BibTeX
@article{miracle2026countylevel,
title = {{County-Level Context and Differential Policy Impacts on Buprenorphine Use Among Medicaid Enrollees with Opioid Use Disorder in Kentucky, 2018–2025}},
author = {Dustin K. Miracle and Svetla Slavova and Patricia R. Freeman and Sergey Tarima},
journal = {Drug and alcohol dependence},
year = {2026},
month = oct,
doi = {10.1016/j.drugalcdep.2026.113394},
url = {https://doi.org/10.1016/j.drugalcdep.2026.113394},
note = {CC BY},
}
RIS
TY - JOUR
TI - County-Level Context and Differential Policy Impacts on Buprenorphine Use Among Medicaid Enrollees with Opioid Use Disorder in Kentucky, 2018–2025
AU - Dustin K. Miracle
AU - Svetla Slavova
AU - Patricia R. Freeman
AU - Sergey Tarima
PY - 2026
DA - 2026/10/10
JO - Drug and alcohol dependence
DO - 10.1016/j.drugalcdep.2026.113394
UR - https://doi.org/10.1016/j.drugalcdep.2026.113394
AB - PURPOSE: To estimate changes in buprenorphine use among Kentucky Medicaid enrollees with opioid use disorder (OUD) after policy changes and pandemic disruptions, and whether impacts differed by county-level context, primarily rurality and, secondarily, opioid treatment program (OTP) availability. METHODS: We analyzed Kentucky Medicaid claims from January 2018 through June 2025, identifying enrollees with diagnosed OUD to construct 10,800 county-month observations. Logistic regression fitted with weighted generalized estimating equations was used for statistical modeling of an interrupted time series (ITS) design to assess changes in the monthly proportion of enrollees with OUD receiving buprenorphine. Interruptions included removal of prior authorization (PA) requirements for transmucosal buprenorphine, methadone coverage initiation, COVID-19-related policy changes, and federal X-waiver elimination. Rurality and OTP availability were evaluated as effect modifiers. RESULTS: The proportion of enrollees with OUD receiving buprenorphine increased from 0.29 to 0.45 across the study period. PA removal was associated with an immediate increase in the odds of buprenorphine use (odds ratio [OR]=1.043; 95% confidence interval [CI]=1.025, 1.061), corresponding to a 1.4-percentage-point increase. X-waiver elimination was associated with a sustained increase in trend (OR 1.007; 95% CI 1.004-1.010). Differential effects by rurality were limited to the COVID-19 period. Counties without an OTP responded more strongly to PA removal than counties with an OTP (P = 0.037). CONCLUSIONS: Removal of administrative and regulatory barriers was associated with increased buprenorphine use among Kentucky Medicaid enrollees with OUD, with effects varying by county-level context, particularly OTP availability.
SN - 0376-8716
SN - 1879-0046
ER -